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1. Introduction 
Neurotrophins are maintained at low concentrations by target tissues. They form highly 
selective interactions with their respective cognate receptors and maintain the viability of 
neurons in the central and peripheral nervous systems. Overlap in receptor specificities for 
neurotrophins, in the tissue distribution of the specific receptors, and in the expression of 
the high affinity receptors enable growth- and survival-enhancing signals to be transduced 
with great efficiency and specificity over a wide variety of neuronal cells. Early studies 
suggested that alterations in neurotrophin levels might underlie the pathogenesis of 
Alzheimer’s disease (AD), Parkinson’s disease (PD), Huntington’s disease (HD) and other 
neurodegenerative disorders (Apfel et al., 1991; Emilien et al., 2000; Hefti, 1983) [reviewed in 
(Lad et al., 2003a)]. Today, a strong link between such a neurodegenerative condition and an 
imbalance in neurotrophin and/or receptor levels has been supported with nerve growth 
factor (NGF) and AD. A disruption or reduction in critical neurotrophin levels thus leads to 
widespread neurodegeneration. Conversely, administration of NGF and/or its related 
family of neurotrophins can potentially play a role in treatment of AD or other degenerative 
neurological disorders. NGF and its peptidomimetics have been proposed and tested in 
animal studies and clinical trials for AD with complex responses observed in some patients. 
Intracellular signaling from the NGF receptors is complex, giving rise to neuronal responses 
that include differentiation, survival, and apoptosis. This review will focus on novel 
approaches to eliciting selectivity of a cellular response, based on alterations in the NGF 
molecule or in the peptidomimetic, that may lead to more effective treatments of AD with 
NGF-related therapeutics. A conceptual comparison to selectivity in other growth factor 
receptor systems, such as epidermal growth factor (EGF) and insulin, will also be made. 
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2. Neurotrophins, their receptors, and neurodegenerative disease 
2.1 Neurotrophin receptor interactions 
Neurotrophins (NTs) are a family of closely related proteins that have diverse functions ranging 
from neuronal development, differentiation, and survival to regulation of axonal and dendritic 
outgrowth, activity-dependent synaptic formation and regulation, cell migration, and cellular 
proliferation (Diamond et al., 1992; Katz et al., 1990; Levi-Montalcini, 1987; Lindsay, 1988; Segal, 
2003). The family of neurotrophins includes nerve growth factor (NGF), brain-derived 
neurotrophic factor (BDNF), neurotrophin 3 (NT-3), and neurotrophin 4 (NT-4) (Ibanez, 1994; 
Lad et al., 2003a) . They possess high sequence homology (ca. ~50%) and adopt similar tertiary 
structures (Fig. 1A) (Bibel & Barde, 2000; Korsching, 1993). The same neurotrophin can affect a 
variety of neuronal populations and, conversely, the same tissue is capable of receiving 
stimulatory inputs from multiple neurotrophins. For example, cholinergic basal forebrain (CBF) 
neurons are attuned to NGF for their maintenance but have been shown to respond to BDNF 
and NT-3 (Bibel & Barde, 2000; Korsching, 1993; Lad et al., 2003a). The viability of dopaminergic 
neurons of the substantia nigra has been linked to the actions of BDNF and NT-4 (Hyman et al., 
1991; Lad et al., 2003a; Parain et al., 1999). Also, BDNF can act on the entorhinal cortex, the 
substantia nigra, and the striatum to affect AD, PD, and PD/HD, respectively (Nagahara & 
Tuszynski, 2011). Each of these neurotrophins binds selectively to a 140-kDa tropomyosin-
receptor-kinase, i.e. NGF to TrkA, BDNF and NT-4 to TrkB, and NT-3 to TrkC (Cordon-Cardo 
et al., 1991; Kaplan et al., 1991; Soppet et al., 1991). Binding to Trk enables the transduction of 
positive signals, i.e. survival and differentiation through its intracellullar tyrosine kinase 
domain. In contrast, all neurotrophins can bind a 75-kDa common neurotrophin receptor, p75 
(or p75NTR), involved in the transduction of negative signals, i.e. growth arrest or apoptosis, 
when expressed exclusively, or positive signals when co-expressed with Trk receptors (Lad et 
al., 2003a). The central and peripheral nervous systems possess multiple neurotrophin-
dependent cells and tissues that demonstrate co-expression of TrkA and p75. 
2.2 Importance of neurotrophins in neurodegenerative disorders   
Numerous studies have now demonstrated an imbalance between neurotrophins and their 
receptors in AD, appearing even in early cognitive defects (Mufson et al., 2007; 2008; Lad, et 
al., 2003a). In cholinergic basal forebrain (CBF) neurons in AD, TrkA and p75 are decreased 
at both the mRNA and proteins levels and NGF mRNA is not changed (Mufson et al., 1995; 
Salehi et al., 2000; S. A. Scott et al., 1995). NGF protein is down in CBF neurons with 
accumulation of NGF in the cortex, suggesting that retrograde transport to provide the 
neurotrophic factor to the basal forebrain is impaired (Schindowski et al., 2008). These 
changes begin to appear in early, pre-clinical stages of cognitive impairment (Ginsberg et al., 
2006; Mufson et al., 1995; Mufson et al., 2000; Mufson et al., 2002; Schulte-Herbruggen et al., 
2008). In addition, the pro-apoptotic proNGF is elevated, suggesting destruction of neurons 
containing p75 (Cuello et al., 2010; Fahnestock et al., 2001). A relationship of neurotrophins 
and their receptors to A toxicity and/or deposition is also becoming apparent (Calissano et 
al., 2010a; Peng et al., 2004). Finally, BDNF, and possibly its precursor form, is implicated in 
neuronal survival imbalance in AD (Garzon & Fahnestock, 2007; Peng et al., 2005), 
particularly in the entorhinal cortex region of the brain (Nagahara & Tuszynski, 2011). 
Consequently, various treatment strategies have been suggested to slow or reverse cognitive 
symptoms, utilizing administration of neurotrophins (Mufson et al., 2008; Nagahara & 
Tuszynski, 2011; Nilsson et al., 2010; Schulte-Herbruggen et al., 2008). 
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Fig. 1. A (left). Folding of the protomer of the four neurotrophins. B (right). Structure of 
dimeric NGF showing the loop regions that interact with the receptors. The yellow bonds 
represent the cystine knot motif. From PDB 1WWW. Note: the variable regions I, II and V 
defined by sequence homology (Ibanez et al., 1991; Ibanez et al., 1993; Ilag et al., 1994) are 
equivalent to loops 1, 2, and 4 (L1, L2, L4) defined in the structure (Wiesmann et al., 1999).  
2.3 Alzheimer’s disease – Treatment strategies  
The pathogenesis of Alzheimer’s disease is related to loss of NGF-mediated survival signals, 
receptor imbalances at the cell surface, and a shift to proprotein forms capable of inducing 
apoptosis. Without these positive signals, the progression of intracellular events that 
ultimately lead to deposition of tangles and plaques occurs uninterrupted. As a result, 
neurodegeneration in the cholinergic basal forebrain leads to cognitive and memory deficits 
demonstrable in AD patients. In the current treatment of Alzheimer’s disease, the use of 
cholinesterase therapies to re-establish critical levels of acetylcholine in the inflicted areas 
are unable to deter the loss of neuronal populations from the CBF and hence to slow the 
progression of the disease (Bierer et al., 1995; Lad et al., 2003a). Based on these findings, an 
appropriate way to reduce or prevent neurodegeneration and maintain viability in 
Alzheimer’s disease is to re-establish NGF signaling within the CBF. Additionally, the 
administered protein must be well-tolerated and stably released over a long period of time 
to achieve its trophic effects (Apfel, 2002). However, the direct administration of NGF to the 
CNS via the circulation is precluded by its inability to cross the blood brain barrier (BBB) 
(Lad et al., 2003a). Furthermore, subcutaneous delivery of NGF elicits acutely painful 
phenomena due to the presence of TrkA receptors at free nerve endings of pain fibers (Apfel 
et al., 1998; Lad et al., 2003a). Finally, gastric secretions would rapidly degrade the protein, 
making oral preparations ineffective.  
Other methods have been considered for delivery of growth factors or protein drugs to the 
brain [for a broad review see references (Alam et al., 2010; Cattaneo et al., 2008)].  Intranasal 
inhalation has been demonstrated to be a promising mode of non-invasive, facile delivery of 
biologics to the brain (Benedict et al., 2011). Monocytes can be loaded to secrete NGF and, in 
proof of principle, shown to migrate across an in vitro BBB model consisting of a brain 
capillary endothelial cell system (Bottger et al., 2010). Encapsulated cell biodelivery is a 
modified gene therapy approach which encapsulates cells in a immunoprotective semi-
permeable hollow fiber synthetic membrane to secrete the protein factor of interest into the 
desired region of the brain (Fjord-Larsen et al., 2010); NGF and glial derived neurotrophic 
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factor (GDNF) are currently undergoing clinical trials with this method in Sweden. 
Transcranial focused ultrasound (FUS) has been shown to transiently-enhance the 
permeability of the BBB and permit antibodies, and probably other macromolecules into the 
intrathecal space (Jordão et al., 2010). Early interest in conjugation of NGF to transferrin or 
transferrin antibodies as a means of transport across the BBB (Friden et al., 1993; Liao et al., 
2001) seems to have waned and shifted toward using this means of cellular uptake for anti-
cancer or diabetic drugs. 
Gene therapy presents the most-advanced, current means of delivering NGF in a cerebral 
region-specific manner (Lad et al., 2003a; Nagahara & Tuszynski, 2011). The two main forms 
of gene therapy that have been used in the delivery of NGF include an in vivo approach and 
an ex vivo approach. The former requires the injection of a viral vector containing the gene of 
interest directly into the region of interest. The latter can be done by transfecting cells with 
the gene of interest in vitro and subsequently transplanting the transfected cells into the 
region of interest. These techniques overcome the problems initially encountered with NGF 
delivery by circumventing the BBB, but require surgical manipulation. Additionally, by 
using viral vectors as the mode of NGF gene delivery into a specific target within the brain, 
these methods provide a stable, renewable system of NGF synthesis, which can help re-
establish receptor levels and counter apoptosis driven by proNGF. However, these forms of 
therapy provide the greatest benefit during early stages of AD before cholinergic deficits set 
in.  
Initial positive results in rat and primate animal models supported studies of NGF in clinical 
trials of AD (Bishop et al., 2008; Eriksdotter Jonhagen et al., 1998; Tuszynski et al., 2005). The 
early clinical trials met with a lack of success due to lack of efficacy, toxicity or both. 
Common problems in these clinical studies, as well as corresponding animal studies, 
include undesirable side effects (e.g. hyperinnervation, sprouting, sympathetic stimulation, 
cachexia, hyperalgesia) (Apfel, 2002; Thoenen & Sendtner, 2002; Winkler et al., 1997) 
[reviewed in (Nagahara & Tuszynski, 2011)]. Intriguingly, a phase I trial of ex vivo NGF gene 
delivery in mild Alzheimer’s disease has shown some promise (Tuszynski et al., 2005). 
Briefly, eight individuals with early-stage, probable AD were administered primary 
autologous fibroblasts, which had been genetically modified to synthesize and secrete NGF, 
via stereotaxic injections to the CBF. This approach was shown to survive grafting into the 
brain and provided stable NGF secretion for up to 18 months in animal studies with 
improvement of cholinergic function and memory (Emerich et al., 1994; Tuszynski et al., 
2002; Tuszynski et al., 2005). At 22 months of follow up, no adverse side effects were 
reported in the clinical trial. Mini-Mental State Exam scores demonstrated a reduction in the 
rate of cognitive decline and 18-fluorodeoxyglucose PET scans demonstrated significantly 
greater cortical glucose uptake (Tuszynski et al., 2005). Although these observations were 
encouraging, results must be considered with caution because of the small data set used and 
the absence of placebo groups. Additionally, NGF demonstrated a large trophic response in 
the CBF of some of these patients. While this response is necessary for target innervation 
during development of the nervous system, an adult brain where the axonal infrastructure 
is well-established might suffer from new and incomplete neuritogenesis in an area 
receiving dense axonal support. Hence, the generation of a more refined therapeutic 
molecule is desirable. Since this ex vivo trial, the focus of the scientific community has 
largely shifted to in vivo delivery with adeno-associated virus (AAV) (Table 1 and 
(Nagahara & Tuszynski, 2011; Nilsson et al., 2010).  
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Interestingly, monoclonal antibodies to NGF were so effective that a Phase III clinical trial 
for treatment of osteoarthritis of the knee was discontinued because of joint failure due to 
excessive wear and tear in the absence of the pain sensation (Lane et al., 2010; Wood, 2010).  
 
Disorder Phase # Delivery* Status Sponsor 
AD   I 8 
ex vivo 
NGF 
end 2005 
some cognitive 
improvement (see 
text) 
UCSD 
AD  II 50 
ICV AAV-NGF 
Cere-110 
Ongoing 
Recruiting 
Ceregene 
AD  Ib 6 
Encapsulated 
cell biodelivery 
NGF 
Ongoing 
NsGene 
(Sweden) 
HIV 
associated 
sensory 
neuropathy  
II 270 
SQ 
NGF 
end 2005 NIAID 
Osteo-arthritis 
of knee  
III 
(a)697
(b)848
IV 
mAb to NGF 
Completed 
Discontinued (see 
text) 
Pfizer 
Table 1. Selected clinical trials of NGF for AD or pain. From clinicaltrials.gov, April 2011. 
*Abbreviations: #, number of patients; ICV, intracerebroventricular; AAV, adeno-associated 
virus; SQ, subcutaneous; IV, intravenous.  
3. Signal transduction by neurotrophins 
3.1 TrkA signaling 
Neurotrophin-mediated signal transduction via the Trk receptors leads to an activation of 
downstream signaling pathways for survival and differentiation (Bibel & Barde, 2000; 
Ibanez, 1994; Kaplan & Miller, 2000; Levi-Montalcini, 1987). NGF binding induces TrkA 
receptor dimerization, transautophosphorylation, and tyrosine kinase ICD activation (Bibel 
& Barde, 2000; Cunningham & Greene, 1998; Cunningham et al., 1997; Friedman & Greene, 
1999). The three major signaling pathways are the phosphotidylinositol-3-kinase (PI3 
kinase)/Akt pathway, the Ras/mitogen-activated protein kinase (MAPK) pathway, and the 
phospholipase C gamma (PLCǄ) pathway (Bibel & Barde, 2000; Kaplan & Miller, 2000; Lad 
et al., 2003a) (See Fig. 2). The PI3 kinase pathway through Akt mediates survival via the 
suppression of apoptotic proteins and accounts for over 80% of neurotrophin-mediated 
survival in neurons (Bartlett et al., 1997; Crowder & Freeman, 1998; Kaplan & Miller, 2000). 
The MAPK pathway, has been implicated in both survival and differentiation, although it 
has also been implicated in such diverse functions as synaptic plasticity and long-term 
potentiation (Kaplan & Miller, 2000; Lad et al., 2003a). Depending on the upstream 
activators and downstream effectors of MAPK, survival, differentiation or both signals can 
be transduced. For the specific induction of differentiation, a sustained MAPK activation is 
necessary. The third signal transduction pathway is the PLCǄ pathway, involved primarily 
in Ca2+ regulation of calcium regulated enzymes, neurotrophin secretion, and synaptic 
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plasticity (Bibel & Barde, 2000; Canossa et al., 1997). These conclusions about distinct 
pathways have been reached by mutagenesis of the Tyr residues of the Trk-ICD and 
demonstrate that these signaling pathways can be individually dissected by manipulation of 
the intracellular initiation of each pathway. TrkB and TrkC have similar signaling pathways 
but with some individual differences because of the different neuronal environment of these 
receptors. The division of TrkA signaling into three discrete, but overlapping signal 
pathways, suggests that pharmaceutical approaches for design of signal selective 
neurotrophic therapeutics (see Section 5.2) may be able to discriminate among selected paths 
toward  cellular outcomes. 
 
 
Fig. 2. Signaling pathways, PI3K, MAPK, PLC , from TrkA phospho-tyrosines to cell 
outcomes. *Phosphorylation of Y785 is dependent on phosphorylaton of Y670, Y674, Y675.  
1Bartlett et al., 1997; Crowder & Freeman, 1998; Rodriguez-Viciana et al., 1994; Holgado-
Madruga et al., 1997. 2Kao et al., 2001; Loeb et al., 1994; Gomez & Cohen, 1991; Qian et al., 
1998; 3Loeb et al., 1994; Canossa et al., 1997; Cunningham et al., 1997. 
Phosphorylation of a specific set of tyrosines ensues within the activation loop of the kinase 
domain. These include two tyrosines located in the juxtamembrane domain (Y490) and C-
terminus (Y785) of Trk that serve as docking sites for adaptor proteins and three tyrosines 
(Y670, Y674, and Y675) within the activation loop that interact with nearby basic residues to 
stabilize a fully functional, active catalytic core and potentiate transduction of downstream 
signals (Bibel & Barde, 2000; Cunningham & Greene, 1998; Friedman & Greene, 1999; 
Grewal et al., 1999; Huang & Reichardt, 2003; Kaplan & Miller, 2000; Lad et al., 2003a). 
3.2 p75 signaling 
Classically, p75 has been thought to be involved in the induction of negative signals like 
apoptosis and growth arrest in oligodendrocytes, Schwann cells, sympathetic neurons, 
motor neurons, and sensory neurons (Bamji et al., 1998; Barrett & Bartlett, 1994; Casaccia-
Bonnefil et al., 1996; Kaplan & Miller, 2000) in a Trk-independent fashion, (Davey & Davies, 
1998; Kaplan & Miller, 2000; Soilu-Hanninen et al., 1999). The co-presence of Trk on a 
neuron silences pro-apoptotic pathways by activation of the pro-survival transcription 
factor, NF-κB, which subsequently activates Akt (Bibel & Barde, 2000; Kaplan & Miller, 2000; 
Khursigara et al., 1999). Sympathetic neurons and basal forebrain neurons that were p75-
deficient in p75-/- mice underwent robust axonal sprouting, hypertrophy, or target 
innervation with naturally-occurring developmental apoptosis being significantly delayed 
(Kaplan & Miller, 2000; Walsh et al., 1999; Yeo et al., 1997; Bamji et al., 1998).  
Without intrinsic catalytic activity, the p75 ICD appears to rely on docking of adaptor 
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proteins. The complexities of the p75 signaling are outlined by representative examples 
shown in Fig. 3.  
 
 
Fig. 3. Some signaling pathways from p75 to cell outcomes. Adaptor proteins interact with 
p75 to generate most cellular effects of a diverse nature. Uncommon abbrevations: NRAGE, 
Neurotrophin receptor-interacting MAGE homolog; NRIF, neurotrophin receptor 
interacting factor, Zn finger transcriptional factor; SC-1, Schwann cell factor 1; NgR, Nogo 
receptor. RhoA, Ras homolog A. (For reviews see Kaplan & Miller, 2000; Bibel & Barde, 
2000; Schecterson & Bothwell, 2010). 1Aloyz et al., 1998; Salehi, et al., 2002; Muller, et al., 
1998; de Chaves et al., 1997; Casademunt, et al., 1999; 2Chittka & Chao, 1999; 3Domeniconi et 
al., 2005; 4Khursigara et al., 1999; 5Susen, et al., 1999; Lad & Neet, 2003. 
The self-interaction of p75 also influences cellular outcome. Biophysical and biochemical 
methods have suggested that homomeric p75 plays a pro-apoptotic role while formation of 
oligomers abolishes this effect and may even serve an anti-apoptotic role (Kaplan & Miller, 
2000; Lad et al., 2003a; Wang et al., 2000). Recently, evidence has been provided to support a 
model in which the formation of an inter-protomer disulfide bond in p75 allows a scissoring 
(or snail-tong) action upon NGF binding that promotes binding of intracellular adaptor 
proteins (Simi & Ibanez, 2010; Vilar et al., 2009).  
As mentioned above (Section 2.2), proneurotrophins may play  significant role in AD, due to 
their ability to stimulate p75 in the absence of positive Trk signals thereby promoting 
apoptosis and death of neurons or glia (Cuello et al., 2010; Fahnestock et al., 2001; Teng, et 
al. 2010). These effects are thought to be mediated by the same pathways (Fig. 3) as 
presented for mature NGF (or other neurotrophins). In addition, soluble oligomers of -
amyloid may also interact with p75 to cause apoptotic signals in neuronal tissue of AD or 
pre-AD patients (Dechant & Barde, 2002; Diarra et al. 2009; Coulson, et al., 2009; Calissano, 
et al. 2010a; 2010b; Peng, et al., 2004; Susen & Blochl, 2005). 
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These studies demonstrate that the interaction of neurotrophins or proneurotrophins with 
p75 can lead to diverse effects that are determined by the developmental state of the 
organism, the particular cell type within which it is expressed, the additional expression of 
co-receptors, receptor oligomerization states, and the binding of intracellular adaptors or 
effectors. The complexity of the p75 pathways suggests that developing signal selective 
muteins for this receptor would be much more difficult than those outlined for the Trk 
receptor (Section 5.2) with its more clearly initiated signaling. Since the response of cells is, 
basically, apoptosis or not, then there would be less advantage at this point in time  in 
generating such reagents for p75.  
4. Molecular analysis of neurotrophin structure and rationale of mutations 
4.1 Conserved and variable regions defined from sequence and 3-D crystallographic 
structures 
Functional data gathered from systematic mutagenesis studies and through the construction 
of inter-neurotrophin chimeras coupled with structural data from crystallographic studies 
have implicated several spatially distinct patches of residues in bestowing receptor 
specificity to each neurotrophin (Casademunt et al., 1999; de Chaves et al., 1997; Grimes et 
al., 1997; Ilag et al., 1994; Lad et al., 2003a; Ninkina et al., 1997; Rabizadeh et al., 1993; J. Scott 
et al., 1983; Walsh et al., 1999; Wiesmann et al., 1999; Yeo et al., 1997) . Sequence alignments 
of NGF, BDNF, and NT-3 (Ibanez et al., 1992; Ibanez et al., 1991; Ibanez et al., 1993; Ilag et 
al., 1994; Kullander & Ebendal, 1994; Kullander et al., 1997) demonstrate that each 
neurotrophin possesses seven variable regions that include the same residue positions. 
These are the N-terminus (residues 1-9), variable region I (ǃ-hairpin loop 1, residues 23-35), 
variable region II (ǃ-hairpin loop 2, residues 40-49), variable region III (ǃ-reverse turn loop 
3, residues 59-66), variable region IV (ǃ-strand, residues 79-88), variable region V (ǃ-hairpin 
loop 4, residues 95-99), and the C-terminus (residues 111-118) (Fig. 1B). This homology in 
clustering translates structurally to variable regions occupying complementary sites on each 
neurotrophin molecule, which are surface-exposed, enabling these regions to function as 
sites of receptor contacts (Fig. 4). These regions also define amino acid residues to target for 
redesign of molecules to alter signaling (see Section 5.2). 
4.1.1 The specificity patch 
Chimeric molecules retaining the amino terminus, carboxyl terminus, and variable region II 
of NGF possessed the ability to differentiate sympathetic neurons and activate the TrkA 
receptor (Ibanez et al., 1991). However, a chimeric molecule that additionally replaced 
residues 3-9 of the N-terminus reduced TrkA binding, activation, and biological activity to 
<1% (Ibanez et al., 1993). Other substitution and deletion studies confirmed the importance 
of the N-terminus in specificity (Kullander et al., 1997; Woo et al., 1995; Kahle et al., 1992; 
Shih et al., 1994). Data from the crystal structure of human recombinant NGF complexed 
with the TrkA-d5 domains showed that the amino terminal residues 6-9, which were not 
well-defined in the original NGF crystal structure, adopted a helical conformation upon 
complex formation with their side chains almost completely buried in the interface 
(McDonald et al., 1991; Wiesmann et al., 1999) (Fig. 4). Within the same region, H4, I6, and 
E11 participated in strong interactions with residues in the ABED TrkA -sheet. The authors 
labeled this region the specificity patch suggesting that the most important Trk receptor-
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binding determinants lie within the amino terminus (Wiesmann et al., 1999). Residues 
spanning the specificity patch, i.e. H4, P5, I6, F7, E11, and F12, are clearly important for 
neurotrophin-Trk interactions and activation.  
 
 
Fig. 4. Schematic representation of dimeric nerve growth factor complexed with two TrkA-d5 
domains. NGF and TrkA (PDB 1WWW) form highly specific interactions at the specificity 
(green dotted oval) and the conserved patch (blue dotted oval). Additional contacts are 
provided by variable loops I, II, and V (loop 4) that form a continuous surface of binding. Each 
TrkA-d5 binding site is derived from contributions from loops in both  protomers in the NGF 
dimer. NGF protomers, pink and orange. 1st TrkA-d5; cyan: 2nd TrkA-d5; grey.  
4.1.2 The variable regions 
The variable regions (Fig. 1B), in general, correspond to loops and surface residues in NGF 
and the other neurotrophins. Generation of NGF-BDNF chimeras identified variable region 
II as holding important receptor binding determinants (Ibanez et al., 1991; Ibanez et al., 1993; 
Ilag et al., 1994; Kullander & Ebendal, 1994; Kullander et al., 1997). The variable region was 
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further dissected into IIa (residues 40-44) and IIb (residues 45-49) (Ibanez et al., 1993). 
Region IIb was shown to play a more pivotal role than IIa when replacement of only the 
latter led to a dramatic reduction in receptor activation and biological activity (Ibanez et al., 
1993). The variable region II, with help from variable region V (loop 4), was also shown to 
confer specificity between NT-3 and NGF (Ilag et al., 1994; Kullander & Ebendal, 1994; 
Kullander et al., 1997). The C-terminal linker region of TrkA could serve as a possible 
binding partner of this region (Wiesmann et al., 1999) (Fig. 4). Therefore, residues within 
variable regions IIa and IIb are considered important for neurotrophin activity, i.e. E41, N43, 
I44, N45, V48, and F49.  
4.1.3 The conserved patch 
Crystallographic data of dimeric NGF complexed with TrkA-d5 demonstrated that 5 of 10 
residues in variable region IV (Y79, T81, T83, H84, and F86) actually form part of the conserved 
patch that interacts intimately with the TrkA-d5 domains (Wiesmann & de Vos, 2001) (Fig. 4). 
This ‘conserved’ patch was so named because 14 of 23 NGF residues are occupied by 
homologous amino acids in BDNF and NT-3, while 8 of 15 TrkA residues are conserved in TrkB 
and TrkC (Wiesmann et al., 1999). The conserved patch forms a continuous binding surface for 
TrkA-d5 and retains high sequence homology across species (Wiesmann et al., 1999) (Fig. 4). 
Variable region IV, a -strand, was specifically shown to retain ~90% homology across species. 
Within this region, T81 and H84 of NGF are replaced by non-homologous amino acids in the 
other neurotrophins, suggesting that variable region IV does form specific contacts with TrkA 
(Ibanez et al., 1993) (Fig. 4). Alanine point mutagenesis of H84 and H75 indicated that these 
residues participated in receptor binding and activation based on a decline in neuritogenesis in 
PC12 cells and the ability to compete for binding sites with radioactively-labeled wild-type NGF 
(Woo & Neet, 1996). Similarly, R100 and R103 showed trends akin to H84 with respect to 
sequence alignment analysis, mutagenesis studies, and crystallographic data. R100 and R103 are 
not only strictly conserved across species but also within the family of neurotrophins. 
Crystallographic data suggested that R103 was the most important binding determinant in the 
conserved patch (Wiesmann et al., 1999) (Fig. 4). [Also see Section 5.1.] Residues V22, I31, F53, 
and F54 within the conserved patch are also highly conserved across species and between 
neurotrophin family members. Alanine substitution of these four residues significantly affect 
TrkA binding by competition assays, intracellular receptor phosphorylation studies, and 
biological activity in PC12 cells (Ibanez et al., 1990; Ibanez et al., 1992; Ibanez et al., 1993; Guo et 
al., 1996). Hence, the conserved patch represents a binding epitope wherein residues help form 
critical interactions between neurotrophins and Trk receptors. 
4.1.4 Summary of important regions and residues of the neurotrophin family 
Sixteen residues of NGF may be identified as most important for function (Table 2) and can 
be designated as the specificity patch (H4, P5, I6, F7, E11, and F12), the variable loops (I31, 
E41, N43, I44, N45, V48, and F49), or the conserved patch (I31, F54, H84, and R103). 
Additional residues, V22, F53, H75, and R100, may not occupy the conserved patch, per se, 
but are as highly conserved as residues residing within or near the patch. Similar 
considerations have been made for BDNF and NT-3 (Ibanez et al., 1992; Ibanez et al., 1991; 
Ibanez et al., 1993; Ilag et al., 1994; Kullander & Ebendal, 1994; Kullander et al., 1997; Suter et 
al., 1992; Urfer et al., 1997). These regions of the NGF molecule were targeted to obtain the 
signal selective muteins discussed in Section 5.2.  
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Specificity Patch – induced N-terminal 
-helix; mainly hydrophobic and some 
H-bond interactions to -strands ABED of 
TrkA-d5. 
NGF:   H4, P5, I6,  F7, E11, F12  
 
BDNF: S4, D5, P6, A7, E11, L12 
Conserved Patch – part of hydrophobic 
core of NGF; interacts with loop EF and 
C-terminus of TrkA-d5 
NGF:    V22, I31*,  F53, F54, H75, H84*, R103  
 
BDNF:  V22, M31, F53, Y54, H75, Q84,  R103 
Specificity for NGF vs NT-3: Loop II- 
 
 
                                                  N-terminus- 
NGF:     E41, N43, I44, N45, V48, F49  
BDNF:   K41, P43, V44, S45     -        - 
NT-3:     E41, K43, T44, G45, P48, V49 
NGF:     P5,  F7 
NT-3:     H5, S7 
Table 2. Important regions of Trk receptor interaction in human NGF and BDNF. Based on 
crystal structure and mutagenesis analysis of NGF (Mahapatra, 2008; Ibanez et al., 1992; Ibanez 
et al., 1991; Ibanez et al., 1993; Ilag et al., 1994; Kullander & Ebendal, 1994; Kullander et al., 1997; 
Wiesmann & de Vos, 2001) and the corresponding regions in BDNF and NT-3. Note: I31 and 
H84 (with *) also participate in Loop 1 and Loop 4, respectively, as well as the conserved patch. 
5. Development of neurotrophin muteins that have potentially improved 
therapeutic properties  
5.1 Receptor selective muteins  
Two interesting, complementary, and useful muteins have helped elucidate the role of the 
two receptors in  neurotrophin action. The first discovery was that mutations in the 32-35, 
loop I area would greatly reduce or eliminate binding to the p75 receptor and leave TrkA 
binding unimpaired (Ibanez et al 1992; 1993). The triNGF (or KKE) mutein contained the 
three mutations, K32A/K34A/E35A, and was used to demonstrate the functional 
interaction between p75 and TrkA in the developing embryo (Ryden, et al., 1997). The 
mutations in the N-terminus of NGF were shown to be important for TrkA binding in 
several laboratories (Section 4.1.1). One noteable mutein was the ∆9/13 mutein that bound 
p75 but not TrkA (Woo et al., 1995), and helped distinguish between differentiation, cell 
cycle regulation, and apoptosis in PC12 cells (Hughes et al., 2001). Utilization of this ∆9/13 
mutein also later indicated a unique role for the ‘high affinity’ binding complex of p75 and 
TrkA in PC12 cells (Lad, et al., 2003b). Indeed, the combination of these two receptor 
muteins, KKE/∆9/13 has been studied, briefly, and shown to have no observable activity, as 
expected (Mahapatra, et al., 2009). Both muteins, KKE and ∆9/13, have been used in a rat 
glaucoma model to interpret the roles of TrkA (neuroprotective) and p75 (neurotoxic) in 
retinal degeneration (Bai, et al., 2010). KKE, but not wild type NGF, has recently been 
reported to partially improve learning in a transgenic APP mouse model (overexpression of 
Swedish and Indiana mutations) with a reduction of soluble cortical ǃ-amyloid levels, but 
with no improvement in long-term memory (Aboulkassim, et al., 2011). These two receptor 
selective muteins have potential as an improved therapeutic for disorders in which either 
TrkA or p75 can be expected, with improved targeting in that case.  
In the opposite direction, a neurotrophin mutein has been made that is less restrictive, rather 
than more restrictive, in binding to Trk receptors. The pan-neurotrophin, PNT, incorporated 
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elements of variable and conserved regions to produce a mutein that binds to all three 
receptors, TrkA, TrkB, TrkC (Ibanez, et al., 1993; Ilag, et al., 1995). To the authors’ 
knowledge, a pan-neurotrophin has not been made that was promiscuous for Trk receptors 
but restricted so as to not bind p75. Such pan-neurotrophins might have utility in the 
treatment of some neurodegenerative disorders in which multiple receptors 
indiscriminately needed extra support (Funakoshi, et al., 1998). 
The observation of a mutation in NGF that affects the pain response suggests that changes in 
signaling from mutations in the ligand have already occurred in nature. A nociceptive 
response is mediated by NGF (Pezet & McMahon, 2006), partly through the TrkA receptor 
and partly through p75 (Einarsdottir et al., 2004; Indo, 2002; Nicol & Vasko, 2007). In a large 
family from northern Sweden, an R100W mutation was uncovered within the coding region 
of NGF. Individuals from this family suffered from insensitivity to both temperature and 
deep pain perception, while retaining normal mental abilities, a disorder termed hereditary 
sensory and autonomic neuropathy type V (HSANV) (Einarsdottir et al., 2004). The R100W 
mutation selectively disrupts binding of NGF to the p75 receptor, while the affinity for TrkA 
receptor is less affected (Covaceuszach et al., 2010). Also, the consequence of the R100W 
mutation on p75 receptor binding is greater for mature NGF rather than proNGF. Signaling 
pathways reflect this selectivity (Capsoni et al., 2011), suggesting that these findings might 
lead to a ‘painless’ NGF protein with therapeutic potential. This NGF mutation is an 
example of a naturally-occurring, receptor-selective change in the neurotrophin. 
5.2 Development of signal selective muteins 
To alleviate the potentially undesirable effects of inappropriate over extension of neurites 
during clinical trials (Section 2.3), designer neurotrophins have been developed (Mahapatra 
et al., 2009). Two survival-specific (or signal-selective, SS) recombinant NGF muteins with 
decreased differentiation potential were designed from a set of rationally selected mutations 
within the specificity, conserved, and variable regions of NGF that may play a 
discriminatory role in signal transduction. One of these muteins is the F7A/H84A/R103A 
NGF triple mutein, also called SS-1 or 7-84-103 for short. The other signal-selective hextuple 
mutein is the K32A/K34A/E35A/F7A/H84A/R103A NGF mutein, or called SS-2 or 
KKE/7-84-103 (Mahapatra et al., 2009). The main difference between the two SS muteins is 
that the KKE addition to the F7A/H84A/R103A mutation simply makes the hextuple 
mutein, SS2, incapable of binding p75 (see Section 5.1).  
Survival in several cell lines and differentiation in PC12 cells were studied with these 
recombinant NGF triple and hextuple muteins and compared to wild type NGF. Each of 
these two muteins induced slightly lower levels of survival in MG139 and PC12 cells with 
greatly reduced neuritogenesis in PC12 cells. Neuritogenesis data indicated that residues 
Phe7, His84, and Arg103 played a critical role in biological activity, in agreement with 
earlier data in the literature (see Section 4). The observed neuritogenic potential of each 
recombinant triple mutein suggested that His84 (conserved patch) played a discriminatory 
role in neurite outgrowth. When His84 was mutated to alanine, to make 7-84-103 and 
KKE/7-84-103, the maximum neuritic response was almost 40% lower than when His84 was 
left unaltered. With 7-84-103 and KKE/7-84-103, a synergistic effect also occurred when 
combining mutations to these three residues. These data suggested that mutations within 
the specificity and conserved patches were more than additive and led to a reduction of 
neuritogenesis. In 7-84-103 and KKE/7-84-103, the two point mutations were made in close 
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proximity within the same spatial region, i.e. His84 and Arg103, within the conserved patch. 
Combining mutations in close proximity may have a cumulative effect on ligand-receptor 
interactions and ultimately reduce the efficiency of some aspects of intracellular signaling. 
When independent single mutations were incorporated in close proximity within critical 
regions at the ligand-receptor interface, survival and differentiation were both affected, with 
a more pronounced effect on neuritogenesis. The greater decrease in differentiation suggests 
the possibility of multiple binding epitopes for the mediation of survival, while suggesting 
more limited patches needed for the induction of differentiation. Comparison with binding 
to immobilized TrkA by surface plasmon resonance suggested that differentiation more 
closely follows affinity than does survival. Furthermore, similarity in measurements 
between the recombinant NGF triple mutein and its KKE hextuple counterpart suggested 
that p75 binding was inconsequential to the induction of survival or differentiation in these 
cell lines. Studies with ectopically expressed receptors in fibroblast cell lines, MG139 
(TrkA+, p75–) and PCNA (TrkA–, p75+), also supported the interpretation that the 
distinction in signaling properties was due to signaling from the TrkA tyrosine kinase 
receptor. 
The 7-84-103 mutein supported better activation of the PI 3-kinase/Akt survival pathway 
than the Ras/MAPK pathway, from which differentiation results. These differences in 
signaling pathways (Akt vs MAPK, see Section 3) indicate that qualitative differences 
result from a different mode of binding to the receptor, or re-orientation of the receptor 
upon binding (see Section 6), and are not simply due to an affinity change that affects all 
signaling pathways equally. In other words, the level of TrkA phosphorylation with 7-84-
103 is more efficiently transferred to MAPK and Akt activation for survival than it is for 
differentiation.  
The discrimination ratio, or ratio of relative (to wtNGF) EC50 values, was 30-fold based on 
the relative EC50 values of 100 and 3.3 for differentiation and survival, respectively 
(Mahapatra et al., 2009). A 30-fold difference in effective EC50 values, in the 
pathophysiological context of an early cognitively diseased brain, might be sufficient to 
greatly reduce unwanted neuritic response while still maintaining neuronal viability. 
Whether the design of these two signal-selective muteins is optimal at this stage, or whether 
further improvement in discrimination between survival and differentiation pathways is 
possible, needs to be examined. 
5.3 How can a transmembrane receptor be stimulated from the outside of a cell and 
initiate different kinds of intracellular signals? 
The intricacies of intracellular signaling from tyrosine kinase ICDs are just now being 
elucidated and are more complicated than might be expected from the simple requirement 
of a receptor dimer to transautophosphorylate tyrosine residues on its ICD domain. 
Activation subsequent to ligand binding to the ECD typically requires phosphorylation of a 
tyrosine in a loop in the active site in order to auto-activate the ICD kinase by moving the 
loop out of its inhibitory position in the active site (Bae & Schlessinger, 2010; Lemmon & 
Schlessinger, 2010). Then the kinase continues to phosphorylate tyrosine residues in the C-
terminal tail of the adjacent ICD of the receptor tyrosine kinase that provide a docking site 
for SH2 domain adaptor proteins or enzymes (Bae & Schlessinger, 2010; Jura et al., 2011; 
Lemmon & Schlessinger, 2010). Three distinct molecular mechanisms have been detected: (i) 
The activation loop interacts directly with the active site of the kinase and blocks access to 
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substrates. (ii) The juxtamembrane region interacts with elements within the active site of 
the kinase to stabilize an inactive conformation. (iii) The C-terminal tail interacts with the 
active site of the tyrosine kinase domain to stabilize an inactive conformation. In each case, 
phosphorylation of the appropriate tyrosine relieves the kinase of its inactivation.  
Evidence from crystallographic studies of the EGF receptor ICD has suggested an allosteric 
mechanism of initiating the signaling cascade (X. Zhang et al., 2006). Two distinct EGFR ICD 
interactions were described: one being a symmetric interaction and the other an asymmetric 
interaction that is capable of explaining how the EGF signal is transduced across the cell 
membrane (X. Zhang et al., 2006). Direct contacts occur between the C-lobe of one ICD, 
acting as an activator, and the N-lobe of another ICD, acting as a receiver. The activator 
kinase ICD destabilizes autoinhibitory interactions that involve the activation loop of the 
receiver ICD. Interactions between the docking proteins, Gab1 and Shc, and the EGFR-ICD 
generate kinetic discrimination between the unliganded and EGF-liganded states (Fan et al., 
2004). The formation of the signal transduction ‘signalosome’ could well depend upon the 
intricate relationship of the ICDs with docking proteins and, thus, be susceptible to the 
manner in which the ligand (neurotrophin mutein or peptidomimetic) brought together two 
Trk ECDs and their connected ICDs with docking partners. In such a scenario, a larger 
protein ligand, such as EGF or NGF, would seem to be more capable of having multiple 
ways to force intracellular interactions in the signalosome than a much smaller 
peptidomimetic with limited ‘hot spots’ for interaction.  
Thus, to explain the NGF mutein data discussed in Section 5.2 (Mahapatra et al., 2009), the 
wild-type NGF might orient the two ICDs in a signalosome that generates a “normal” ratio 
of MAPK to Akt activation. In the survival-selective muteins, 7-84-103 and KKE/7-84-103, 
the orientation of the ICDs or juxtamembrane regions would have been altered such that the 
output ratio has been shifted in favor of Akt over MAPK signaling and, hence, survival over 
neuritogenesis.  
6. Neurotrophin peptidomimetics and cell signaling 
The use of small molecules is often preferable over the use large proteins as 
pharmacological agents due to their stability, lower manufacturing costs, ability to pass 
tissue barriers and good pharmacokinetic profiles. The small molecules can be rationally 
designed to mimic a region of the ligand that is involved in binding to the receptor or 
involved in activation of the receptor, thus the term ‘peptidomimetics’. Binding of a 
peptidomimetic to the target receptor may not necessarily result in activation and thus 
these mimetics may act as antagonists or agonists, depending on their ability to induce a 
functional response. An inability to induce a functional response would mean that a small 
molecule with good affinity would be a good inhibitor/antagonist. Two terms that are 
useful in the design of mimetics are pharmacophore and ‘hot spots’. The term 
‘pharmacophore’ relates to the steric and electronic interactions of the mimetic that are 
necessary to bind to the target receptor, either as an agonist or as an antagonist. The term 
‘hot spot’ refers to the regions on the target protein that specifically interact with a ligand 
to induce a biological response. Hence, the rational design of mimetics utilizes the 
information from both the pharmacophore and the hot spots to create libraries of 
compounds that have subtle structural differences, but significant functional differences 
(Peleshok & Saragovi, 2006). 
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6.1 Early neurotrophomimetics  
Early studies with cyclized monomeric peptides representing the four loop regions (see Fig. 
1B) of NGF (LeSauteur et al., 1995) produced antagonists that competed with NGF for 
binding and inhibited its activity. The most potent antagonist was derived using amino 
acids from loop 4 (amino acids 92-97); the peptides designed around loop 2 (amino acids 43-
48) or loop 1 (amino acids 30-35) were less effective. As expected, potency was also effected 
by length and amino acid substitution, with linear peptides showing no activity. Formation 
of the -turn is not simply defined by the amino acid sequence and the activity requires 
mimicking of the 3-dimensional conformation (LeSauteur et al., 1995). Interestingly, in cells 
expressing both TrkA and p75, the addition of an anti-p75 monoclonal antibody (MC192) 
that synergizes with NGF caused the antagonistic loop 4 mimetics to behave as agonists 
with phosphorylation of TrkA and induction of neurites (Maliartchouk et al., 2000). Peptides 
that formed type I or type L-R turns showed greater activity in presence of MC192, 
suggesting that binding between TrkA and the loop 4 region may require an ‘induced fit’ 
mechanism (Beglova et al., 2000).   
6.2 Small molecule Trk agonists and antagonists 
Other studies, however, reported that cyclized monomeric loop 4 peptide mimetics had to 
be presented as dimers of cyclized peptides to show agonistic activity  (Xie et al., 2000). 
Their dimeric cyclized peptide, involving amino acids 92-96, showed NGF like activity and 
induced neurite outgrowth and Akt activation in a TrkA- and ERK- dependent manner. 
Thus, the dimeric peptide was able to induce an NGF-like signal, by binding to and 
activating TrkA. Modifications in the peptide sequence abolished the agonistic activity, 
suggesting specificity conferred by the amino acid sequence (Xie et al., 2000). On the other 
hand, dimerization of a peptidomimetic does not always behave as expected. Conversion of 
a monovalent peptidomimetic into a divalent mimetic by chemical coupling resulted, 
surprisingly, in an antagonist (Brahimi et al., 2010). 
Loop 1 peptidomimetics show very unique activity. The loop 1 region (amino acids 30-35) 
has not only been implicated in activation of TrkA, but amino acids K32, K34 and E35 are 
extremely important for p75 binding (Ibanez et al., 1992; Ibanez et al., 1993) (see Section 5.1). 
Therefore, this region influences both TrkA and p75 binding. Cyclized monomeric 
peptidomimetics designed using the -turn of NT-3 are good TrkC agonists, however some 
of the peptides showed partial agonistic response towards TrkA. Interestingly, some of the 
mimetics were able to induce a neurite outgrowth response through TrkA or TrkC, but 
failed to induce a survival response on TrkA-only expressing cells (Zaccaro et al., 2005). 
Neurite outgrowth studies were done using PC12 cells which express both TrkA and p75, 
whereas survival studies were done using TrkA-only expressing 3T3 cells. The authors, 
therefore, argued that this peptidomimetic binds to a special ‘hot spot’ on TrkA that is 
accessible only when p75 is co-expressed. The co-expression of p75 with TrkA could result 
in formation of the TrkA-p75 heteroreceptor complex and binding of p75 to TrkA, perhaps, 
results in conformational changes in the receptor, making the ‘hot spot’ accessible (Zaccaro 
et al., 2005). The D3 mimetic in this series was also tested in  cognitively impaired aged rats 
and showed rescue of the cholinergic phenotype in the cortex and nucleus basilis (Bruno, et 
al., 2004) and to improve learning and reduce –amyloid in APP mice (Aboulkassim, et al., 
2011). 
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6.3 Small molecule p75 agonists and antagonists 
In contrast, Longo’s group made loop 1 mimetics (LM11A-24 and LM11A-31) that targeted 
p75 and were able to induce a survival response through p75 in hippocampal neurons 
(Massa et al., 2006). Hippocampal neurons express TrkB and p75, but not TrkA; therefore, 
this survival induced by loop 1 mimetics was suggested to result via p75. They further 
showed that the survival response was lost in hippocampal neurons from p75-/- mice and 
that these peptides showed competitive binding to p75 but not TrkA, supporting the 
interpretation that the activity was through p75. The survival response observed was 
mediated by NF-κB and the PI3K-Akt pathway (Massa et al., 2006). They further 
demonstrated that the mimetics were able to rescue the neurons from proNGF-induced 
(Massa et al., 2006) or A-induced (Yang et al., 2008) cell death, which have implications for 
Alzheimer’s pathogenesis. NGF, even though it can bind p75, was not able to prevent the 
A-induced neuritic dystrophy. Differences between the signaling by the mimetics vs NGF 
via p75 were also observed. Both NGF and the mimetics were able to inhibit the ability of 
A to down regulate Akt signaling; in contrast, the peptidomimetics demonstrated p75-
dependent inhibition of A-induced GSK3b and A-induced JNK activation, whereas NGF 
could not affect these latter two activities. Thus, these loop 1 peptidomimetics induced 
additional survival promoting cell signaling via p75 in presence of A, not observed with 
NGF via p75 (Yang et al., 2008). Hence, the selectivity progressed from receptor to signaling 
pathway. From another laboratory, a different loop1-loop4 mimetic was shown to have 
some ability to reduce neuropathic pain in a rat model (Colangelo, et al., 2008).  
6.4 The prognosis for signal selective mimetics 
These studies with NGF peptidomimetics illustrate the advances that have been made as 
well as outlining the complexities involved. Whether a monovalent or a divalent (dimeric) 
NGF peptidomimetic is functional and most appropriate for clinical use is, as yet, 
unresolved. Good NGF mimetics at this stage appear to be D3 or its derivatives and LM11A-
24 or LM11A-31, although each may potentially be useful for a distinct purpose. Also being 
developed are TrkB (O’Leary & Hughes, 2003; Fletcher, et al., 2008; Fletcher & Hughes, 2009) 
and TrkC (Brahimi, et al., 2009; Chen, et al., 2009; Liu, et al., 2010) antagonists/agonists. 
BDNF mimetics have made progress toward a useful therapeutic reagent with efficacy 
studies in rodents (Massa et al., 2010). Some of these neurotrophin reagents show receptor 
selectivity, as well as selective cellular response, i.e. survival vs differentiation (Saragovi et 
al., 2009).  Whether a small peptidomimetic or a modified, full-length NGF protein will 
ultimately prove to be the most effective clinical reagent for treatment of AD is an open 
question at present. The pharmacokinetic advantages of a small molecule mimetic may 
eventually outweigh the limited information content, relative to the full length protein, 
provided by such a peptide. In other words, will the chemists be able to design sufficient 
specificity and selectivity into the peptidomimetics to compete with the potential specificity 
of a 26 kDa neurotrophin protein with its myriad interaction sites? The answer in some cases 
for selective signaling appears to be yes (Zaccaro et al., 2005; Longo, et al., 2007; Yang et al., 
2008). Conversely, will the means of delivery (intracerebroventricular injection, intranasal 
inhalation, encapsulation) of a full-length neurotrophin mutein be developed sufficiently to 
make easy administration to the AD brain competitive with a, perhaps, less effective small 
molecule that is easily delivered? In either case, exquisite signal selectivity to allow ultra-
focus may be most effective and/or desirable. 
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7. Other growth factors with cellular signaling selectivity 
Neurotrophins are not the only ligand-receptor system in which molecular engineering 
approaches have been employed to improve the therapeutic potential.  Mutants of both 
insulin and tumor necrosis factor (TNF) have also been developed with enhancement of 
their therapeutic properties. TNF was re-designed with the intent of improving its death-
inducing targeting toward tumors and reducing its systemic side effects  (Wajant, et al., 
2005; Gerspach, et al., 2009). This attempt is a true challenge with a multifunctional, 
pleiotropic cytokine such as TNF; nevertheless some progress has been made. Similarly, 
insulin has been engineered to improve its stability as a single chain (Hua, et al., 2008), its 
stability as a zinc ‘stapled’ hexamer with even longer lasting attributes (Phillips, et al., 2010), 
and its selectivity for the insulin receptor over the non-cognate IGF-1 receptor (Zhao, et al., 
2009). A reported 3-fold improvement in receptor selectivity has the potential of reducing 
colorectal cancer risk for diabetic patients using insulin replacement therapy (Zhao, et al., 
2009). How well these receptor and/or signal selective mutant cytokines/hormones may 
work in therapeutic trials is still uncertain. 
8. Conclusions and the future 
The importance of ligand-receptor interactions in AD and other neurodegenerative 
conditions is well appreciated. Protein levels and mRNA levels for both TrkA and p75 
receptors are reduced in early AD even in the presence of stable NGF expression. A shift 
from mature NGF to proNGF, which binds p75 and induces apoptosis, has also been 
observed. Thus, the neurodegeneration in the basal forebrain in AD is aggravated by a 
reduction in signaling from TrkA receptors coupled with apoptotic signaling by proNGF 
binding to p75 (see Section 2.2). Animal studies and clinical trials of NGF gene delivery 
show promise in curtailing neuronal apoptosis in Alzheimer’s disease or animal models. 
However, the CBF in some patients demonstrated a trophic response of immature neuritic 
processes, i.e. neurite outgrowth where it was not needed or useful. Adult brains with AD 
possessing an established axonal network may be adversely affected by this type of aberrant 
neuritogenesis. Survival support for existing neurons is preferable without inducing de novo 
connections that might be dysfunctional. A key goal for future intervention of this type is to 
promote viability of specific neurons without causing neuritic or axonal overgrowth. 
The possibility and potential of designer growth factors has been highlighted in this review. 
Step-wise mutagenesis of NGF led to the generation of survival-selective muteins that are 
potentially therapeutic lead candidates for Alzheimer Disease or other neurodegenerative 
disorders. Two mechanism-selective recombinant NGF muteins show a marked difference 
in the ratio of survival to neuritogenesis in several assays, including signaling through the 
Akt survival pathway. Thus, in principle one can separate intracellular signaling pathways 
for a receptor via modifications to its ligand. Successful parallel studies with molecular 
engineering of insulin and TNF support this viewpoint. Structural studies of other receptor 
systems, e.g., EGF, have provided a logical, molecular basis for understanding how these 
signals may be separately activated. Progress with small molecule mimetics of NGF that are 
agonists show some of the same receptor- and signaling- selectivity that receptor- or signal-
selective muteins of the parent protein do. The future should provide major advances in this 
exciting area of improving upon nature and developing novel treatments for AD. Coupling 
of designer neurotrophins with improved delivery to the brain provides great promise. 
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10. Nomenclature 
7-84-103, NGF mutein, F7A/H84A/R103A 
A, beta amyloid 
AD, Alzheimer’s disease 
APP, amyloid precursor protein 
Akt, a ser-thr kinase (also PKB) 
BDNF, brain derived neurotrophic factor  
BBB, blood brain barrier 
CBF, cholinergic basal forebrain 
ECD, extracellular domain  
EGF, epidermal growth factor  
EGFR, EGF receptor  
GSK3b, glycogen synthase kinase 3b 
ICD, intracellular domain  
IGF-1, insulin like growth factor 1 
JNK, c-Jun N-terminal kinase 
KKE, K32A/K34A/E35A NGF mutein  
KKE/7-84-103, hextuple mutein, K32A/K34A/E35A/F7A/H84A/R103A NGF mutein 
MAPK, mitogen-activated protein kinase  
NF-κB, Nuclear factor kappa-light-chain-enhancer of activated B cells 
NGF, nerve growth factor (-subunit)  
NT-3, neurotrophin 3  
NT-4, neurotrophin 4  
p75, common neurotrophin receptor  
PC12, pheochromocytoma 12 cell line  
PI3K, phosphoinositide 3-kinase 
PLC, phospholipase C gamma 
proNGF, precursor form of NGF 
TNF, tumor necrosis factor alpha 
Trk, tropomyosin related kinase  
Δ9/13, NGF mutein with residues 9 through 13 deleted 
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